Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

... responses against the matching H5 antigen and the conserved NP and M2 antigens were detected in a majority of subjects receiving the trivalent vaccine. Responses against conserved antigens could provide protection against serious disease or death during an ...

Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients

... immune responses in humans. The ALVAC(2) virus contains the genes for five antigens -- molecules that induce an immune response -- that are commonly found in melanoma tumors. These antigens stimulate T-cells within the immune system to hone in on melanoma cells, ...

Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation

... leading vaccine technologies, specifically a delivery platform for antigens and adjuvants that can facilitate the development of a broad range of ... diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms ...

AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial

... developed substantial antibody or T cell responses to all three CMV antigens in the vaccine. Preliminary results suggest that both the CD4 and CD8 ... readily detectable immune responses to all three vaccine-expressed antigens and at both dosage levels. It is these types of responses, both cellular ...

A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds

... bone marrow, umbilical cord blood, and peripheral blood from donors. The antigens on the surface of donated cells must be compatible (determined by a method ... rejection. The use of embryonic stem cells, which have low levels of these antigens and may therefore be less likely to provoke a defensive reaction by the ...

CEL-SCI Corporation Releases Letter to Shareholders

... on a tumor and attack that tumor only in one way. There are many antigens that need to be attacked to overcome the very complex tumor defense mechanisms and the constant mutation of the tumor antigens cannot be addressed with a 'one key fits all' approach. 3) They act ...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

... metastatic melanoma whose disease had been minimized by other therapies. The study entitled "Phase II Trial of Dendritic Cells Loaded with antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Anti-Tumor Vaccines in Patients with Metastatic Melanoma," was published ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... its L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune responses that would be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas. ...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

... to the GALT and promotes their maturation. This unique aspect of its function results in recruitment of dendritic cells that have captured tumor antigens while in the peripheral circulation. Following maturation, these dendritic cells activate Natural Killer (NK) and Natural Killer T-cells (NK-T) of ...

AlphaVax Announces Promising Results in Melanoma Studies

... studies conducted at MSKCC demonstrate the ability of AlphaVax's virus-like replicon vector particles (VRP) encoding melanoma-specific tumor antigens to reduce melanoma tumor burden in a state-of-the-art murine melanoma model. Jedd D. Wolchok, M.D., Ph.D., Lab Head and faculty member at MSKCC, ...

Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting

... domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion's SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor ...

CEL-SCI Corporation Releases Letter to Shareholders

... system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they ...

IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729

... 9:45-10:45 am - # 41: T Cell Immunity Assessed by Intracellular Cytokine Analysis Following Stimulation of Whole Blood or PBMCs with Microbial antigens of Mitogens Sunday, 9:45-10:45 am - # 405: Presence of IgG Anti-IgE Autoantibodies in Chronic Urticaria and Atopic Dermatitis ...

Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds

... laser burns in one of the retinas of 15 mice. They then injected either the burned or the unburned eyes of each mouse with the antigen, Ovalbumin. antigens are substances that the body perceives as foreign and against which it mounts a defense. They found that immune privilege was disrupted in both ...

Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa

... used childhood vaccine, did not interfere with the protective immune responses to each of the vaccine components. The childhood vaccine contained antigens for Diphtheria (D), Tetanus (T), whole-cell pertussis (Pw) and haemophilus influenzae B (Hib). In countries where a malaria vaccine is needed most, ...

Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes

... transplantation, bone marrow and peripheral blood donors are examined for genetic compatibility with the patient by comparing their human leukocyte antigens (HLAs). Current estimates from the National Marrow Donor Program donor registry suggest that the probability of finding a matched unrelated adult ...

Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection

... and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these ...

MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research

... cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies ...

VIRxSYS to Host a Web Conference to Announce Clinical Trial Update

... primate data from the study of VRX1023, a new vaccine approach that uses a lentiviral vector expressing HIV antigens. In the study, VRX1023 delivered antigens that induced long-lasting cellular and humoral immune responses, better than those seen with other viral vectors, a powerful approach used to elicit ...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

... is transported by the M-cells into the small intestinal Peyer's Patches, where it recruits circulating immature dendritic cells bearing tumor antigens to the GALT and induces their maturation. DC maturation in the presence of tumor antigens and lymphoid effector cells induces a strong systemic ...

Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation

... antigen, the entire tumor regressed following the infusion. The scientists postulated that the patient's immune response was broadened to other antigens expressed by the tumor cells. Follow-up tests showed T cell responses to two additional tumor antigens, MAGE-3 and MART-1. Researchers in Yee's ...

Nventa Develops Proprietary Vaccine Adjuvant

... robust, antigen-specific cellular immune responses in humans, enhancing the effect of both therapeutic and prophylactic vaccines against targeted antigens and pathogens." Nventa intends to incorporate Poly-ICR into its future CoVal(TM) therapeutic compound programs. The company is also currently in ...

Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine

... and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these ...

New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma

... MAGE-A3 ASCI as a potential novel cancer therapy. Validation of a predictive gene signature, combined with selection of patients who express cancer antigens of interest, may allow GSK to improve predictions of a patient's clinical response to treatment with cancer immunotherapeutics," said Johan ...

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies

... of non-human primates. The presentation at AACR shows that all BiTE antibodies are active in eliminating cells expressing the respective target antigens of human and macaque origin. The four BiTE antibodies with specificity for EGFR, HER2/neu and IgE target antigens, all showed high potency as ...

Novavax Reports Fourth Quarter and 2007 Year-End Financial Results

... of 2008. The initial results from our pandemic influenza study bode well for our seasonal program, because immunogenicity of the avian H5N1 antigens is not as robust as seasonal flu due to the fact that the H5N1 is not a human virus. -- Announced two additional new vaccine programs, one for ...

Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting

... is transported by the M-cells into the small intestinal Peyer's Patches, where it recruits circulating immature dendritic cells bearing tumor antigens to the GALT and induces their maturation. DC maturation in the presence of tumor antigens and lymphoid effector cells induces a strong systemic ...

Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future

... anti-tumor activity of three other BiTE antibodies targeting solid tumors by EpCAM (CD326), EphA2 or CEA antigens. All three tumor-associated antigens are found on many solid tumors. In addition, the article provides a detailed description of the mode of action of BiTE antibodies, comparing it to ...

Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections

... HIV infected individuals on fully suppressive antiretroviral therapy who were treated a single time with either 0.1, 0.4 or 0.8 mg of multiple HIV antigens encoding plasmid DNA, the active substance in DermaVir Patch. The same antiretroviral drug regimen was continued during the one-year follow-up. ...

New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity

... covers the methods and compositions of formulating nanoemulsion vaccines, a unique coupling of oil, water, and antimicrobial surfactant together with antigens from specific pathogens. Studies in animals demonstrate these vaccines easily penetrate the mucous membrane, where dendritic cells rapidly engulf ...

Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials

... diseases. Hawaii Biotech has developed a proprietary protein production platform that has application to the production of proteins for use as antigens in infectious disease vaccines. In addition, to its work on a dengue vaccine, the company is also developing vaccines for West Nile virus and ...

Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas

... cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for ...

IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients

... of 29 evaluated patients (62%) showed a significant increase in TAA-specific cytokine-producing cells. o The most frequently recognized antigens after vaccination with UVIDEM were gp100 and MAGE. -- UVIDEM was well tolerated with only one possibly related serious adverse event ...

Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog

... its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and ...

Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza

... and in less restrictive conditions than conventional vaccines. Vical systematically tested prototype vaccines using a range of viral antigens to determine the optimum combination of conserved and variable targets. The company then systematically tested different formulations for ...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

... role in controlling T cell responsiveness to antigens by regulating the T cell receptor signaling pathway. Because the T cell response to antigens is one of the primary components of certain ... development and to regulate T cell responses to antigens via the T cell receptor signaling pathway," said ...